The EGFR inhibitor's subcutaneous version heats up competition with AstraZeneca's Tagrisso in the front-line EGFR-mutated NSCLC space.
In a deal announced Thursday, CAMP4 said it will receive $17.5 million upfront from GSK and will be eligible for development and commercial milestone payments as well as tiered royalties on ...
Biomarker Therapy in 2025: More Lung Cancer Options, Competition in New Drug Classes, ctDNA Advances
This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...
The committee recommended the combo for patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations based on data from the MARIPOSA trial.
The company said the combo could help overcome resistance to EGFR inhibitors in patients whose tumors harbor the mutation.
The firm is submitting data showing that a one-time treatment with ST-920 led to a positive annualized estimated glomerular filtration rate slope.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback